Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Artelo Biosciences Inc logo
    ARTL

    Artelo Biosciences Inc

    MaveScore 18 Low model confidence
    Last Price US$1.09 As of Jul 10, 2026
    Market Cap US$3.2m Company size context
    7D Performance -1.81% Past 7 days
    1Y Performance N/A Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Aug 31, 2022

    1410 days old

    Market price date

    Jul 10, 2026

    1 day old

    Coverage

    14/16

    2 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 18 Low confidence

    Stored data quality

    Freshness and coverage checks

    14/16 Partial or delayed snapshot

    Quality

    13/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    0/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    4/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    1/15 Weak

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Artelo Biosciences Inc Overview

    Industry: Biotechnology

    Sector: Healthcare

    Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial Read More

    Artelo Biosciences Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    Artelo Biosciences Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed May 14, 2026

    Quarterly result summary

    Latest company-filed earnings material is available for source review.

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    SEC filing Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 8-K Mar 17, 2026 SEC filing FORM 10-K Feb 24, 2026 SEC filing FORM 10-Q Nov 12, 2025 SEC filing FORM 10-Q Aug 13, 2025 SEC filing FORM 8K Jul 11, 2025 SEC filing FORM 10-Q May 13, 2025 SEC filing FORM 10-K Mar 03, 2025

    Recent News



    ARTL - Artelo Biosciences Inc Latest SEC Filings
    Thu, 02 Jul 2026 05:13:53 GMT
    Artelo Biosciences (ARTL) Reveals Positive Preclinical Data in N
    Wed, 01 Jul 2026 15:03:40 GMT
    Artelo Biosciences Appeals Nasdaq Delisting Decision
    17 hours ago

    Earnings Per Share

    Score 0.00/5
    Artelo Biosciences Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 3.61/5
    Artelo Biosciences Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Artelo Biosc... ARTL US$3.2m
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Net Margin

    Score 3.92/5
    Artelo Biosciences Inc commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Artelo Biosc... ARTL US$3.2m
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 4.56/5
    Artelo Biosciences Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Artelo Biosc... ARTL US$3.2m
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Artelo Biosciences Inc logo

    Artelo Biosciences Inc

    US$1.09

    US$3.2m

    -1.81%

    N/A